← Leaderboards
Claudia Katharina Petritsch
University Of California, San Francisco
$3,588,663
Attributed
$4,467,761
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $875.2K · FY2012–25$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,467,761 · 5
By mechanism
R01$3,332,283 · 2
U54$699,603 · 2
R21$435,875 · 1
Top collaborators
- Charles David James5 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Torsten Wittmann$8,201,015
- Sabrina Miriam Ronen$18,398,578
- Joanna Phillips$10,725,718
- Justin Meyerowitz$106,809
- Faranak Fattahi$6,979,753
Others in their field
Top investigators on “Malignant - Descriptor”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,073,740,423
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$245,977,428
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant - DescriptorMolecularMalignant NeoplasmsMouse ModelGrowthCellsIn VivoResponseIn VitroSignal TransductionProliferatingLeadCell DivisionSelf-RenewalTumorBrain NeoplasmsNeoplastic Cell TransformationMutationImageHeterogeneityInsightNeoplastic CellBrainResistance
Grant awards (17)
NEUROPATHOLOGY/TISSUE BANK CORE$130,357
U54 · FY2025 · CA · contact PI
NEUROPATHOLOGY/TISSUE BANK CORE$123,190
U54 · FY2024 · CA · contact PI
NEUROPATHOLOGY/TISSUE BANK CORE$124,188
U54 · FY2023 · CA · contact PI
NEUROPATHOLOGY/TISSUE BANK CORE$150,594
U54 · FY2022 · CA · contact PI
NEUROPATHOLOGY/TISSUE BANK CORE$171,274
U54 · FY2021 · CA · contact PI
Investigating ASPM regulation of asymmetric division for therapeutic opportunities$237,750
R21 · FY2017 · NS · contact PI
BRAF Mutation in Malignant Astrocytoma Origin, Evolution, and Response to Therapy$356,473
R01 · FY2016 · NS
A causal role for asymmetric cell division defects in glioma initiation$320,588
R01 · FY2016 · CA · contact PI
Investigating ASPM regulation of asymmetric division for therapeutic opportunities$198,125
R21 · FY2016 · NS · contact PI
BRAF Mutation in Malignant Astrocytoma Origin, Evolution, and Response to Therapy$356,473
R01 · FY2015 · NS
A causal role for asymmetric cell division defects in glioma initiation$320,588
R01 · FY2015 · CA · contact PI
BRAF Mutation in Malignant Astrocytoma Origin, Evolution, and Response to Therapy$351,981
R01 · FY2014 · NS
A causal role for asymmetric cell division defects in glioma initiation$310,970
R01 · FY2014 · CA · contact PI
BRAF Mutation in Malignant Astrocytoma Origin, Evolution, and Response to Therapy$341,104
R01 · FY2013 · NS
A causal role for asymmetric cell division defects in glioma initiation$301,353
R01 · FY2013 · CA · contact PI
BRAF Mutation in Malignant Astrocytoma Origin, Evolution, and Response to Therapy$352,165
R01 · FY2012 · NS
A causal role for asymmetric cell division defects in glioma initiation$320,588
R01 · FY2012 · CA · contact PI